Microcap Ledger Contineum Therapeutics, Inc. $CTNM
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Select Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
- Shares outstanding
- 23,099,173 [10-Q 2025-10-30]
What the company doesAI summary of filing
Contineum Therapeutics is a clinical-stage biopharmaceutical company developing small molecule drug candidates targeting neuroscience, inflammation and immunology indications. The company's lead asset, PIPE-791, is a brain-penetrant LPA1 receptor antagonist in Phase 2 development for idiopathic pulmonary fibrosis and Phase 1b development for chronic pain; a Phase 2 trial in IPF was initiated in December 2025. Its second drug candidate, PIPE-307, is a selective M1 receptor inhibitor in development for depression and relapse-remitting multiple sclerosis through a partnership with Johnson & Johnson, which has sole discretion over further development. The company is pre-revenue and funds its operations through capital raised from investors. [10-K 2026-03-05]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$29.61M | −$27.77M | $14.71M | [10-Q 2026-07-30] |
| FY ended Dec 2025 | — | −$59.98M | −$55.31M | $75.60M | [10-K 2026-03-05] |
| FY ended Dec 2024 | $0.00 | −$42.26M | −$32.84M | $21.94M | [10-K 2025-03-06] |
- Quarterly cash burn
- −$13.88M
- Cash runway Estimate
- ~3.2 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-08-13 | 18,994,104 | [10-Q 2024-08-14] |
| 2025-02-28 | 25,871,549 | [10-K 2025-03-06] |
| 2025-05-09 | 25,871,549 | [10-Q 2025-05-14] |
| 2025-07-31 | 28,041,895 | [10-Q 2025-08-05] |
| 2025-10-27 | 23,099,173 | [10-Q 2025-10-30] |
- Shelf registration
- S-3 filed 2025-05-14; declared effective 2025-05-23 [S-3 2025-05-14]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-08 | Stengone Carmine N. | exercise | 2,500 | $1.01 | [4 2026-09-08] |
| 2026-09-08 | Stengone Carmine N. | sell | 2,500 | $16.46 | [4 2026-09-08] |
| 2026-08-03 | Stengone Carmine N. | exercise | 2,500 | $1.01 | [4 2026-08-03] |
| 2026-08-03 | Stengone Carmine N. | sell | 2,500 | $16.01 | [4 2026-08-03] |
| 2026-07-09 | Lorrain Daniel S. | exercise | 25 | $1.01 | [4 2026-07-10] |
| 2026-07-09 | Lorrain Daniel S. | sell | 25 | $16.00 | [4 2026-07-10] |
| 2026-07-08 | Lorrain Daniel S. | exercise | 1,015 | $1.01 | [4 2026-07-10] |
| 2026-07-08 | Lorrain Daniel S. | sell | 1,015 | $16.00 | [4 2026-07-10] |
| 2026-07-08 | Stengone Carmine N. | exercise | 2,500 | $1.01 | [4 2026-07-08] |
| 2026-07-08 | Stengone Carmine N. | sell | 2,500 | $16.00 | [4 2026-07-08] |
| 2026-07-01 | Lorrain Daniel S. | exercise | 4,183 | $1.01 | [4 2026-07-02] |
| 2026-07-01 | Lorrain Daniel S. | sell | 5,852 | $15.67 | [4 2026-07-02] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-14 | 8-K | Other events |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-30 | 10-Q | Quarterly report |
| 2026-07-30 | 8-K | Results of operations |
| 2026-07-27 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-07-17 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-07-13 | 8-K | Regulation FD disclosure |
| 2026-06-26 | 8-K | Shareholder vote results |
| 2026-05-15 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-05 | 10-Q | Quarterly report |
| 2026-05-05 | 8-K | Results of operations |
Alerts for $CTNM
Email me when Contineum Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.